-- Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 loss--of--function cancers; expect to initiate Phase 1b/2a clinical trial in solid tumors in mid-2026 -- SOUTH SAN ...
-- Study highlights importance of cancer driver biology in translating results from lab to patients -- -- Findings validate proprietary OncoSLX Platformâ„¢, a pharmacogenetic approach that captures the ...
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Leapfrog Bio, a clinical-stage precision oncology company dedicated to discovering and developing novel targeted therapies for cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results